Alterity Therapeutics Limited
Save
13.78M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease.

Similar securities

Based on sector and market capitalization

Report issue